Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10442000 | 1.00 | CA1 (0.42) | — | |
| SCHEMBL12457356 | 0.97 | CA1 (0.43) | — | |
| SCHEMBL1831914 | 0.97 | — | — | |
| SCHEMBL1715636 | 0.97 | CA1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4573840 | 0.97 | — | — | |
| SCHEMBL13827708 | 0.97 | CA1 (0.43) | — | |
| SCHEMBL19632110 | 0.97 | CA1 (0.43) | — | |
| SCHEMBL441840 | 0.97 | — | — | |
| SCHEMBL8017816 | 0.93 | — | — | |
| SCHEMBL640121 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| CN-106536508-B | For treat Alzheimer disease have the active compound of cholinergic muscarinic M1 receptor positive allosteric regulator | 武田药品工业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-109952302-A | Muscarine M1 receptor forward direction allosteric modulators | 苏文生命科学有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-109923113-A | novel isoxazolyl ether derivatives as GABA A α 5 PAM | 豪夫迈·罗氏有限公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-109863140-A | 3- oxo -2,6- diphenyl -2,3- dihydrogen dazin -4- formamide | 拜耳医药股份有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-104910148-B | Aminotriazole(ATA) and pyridine and its as kinase inhibitor purposes | 西格诺药品有限公司 | 2017-06-27 | — | — | CN | disclosed |
| CN-106536508-A | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | 武田药品工业株式会社 | 2017-03-22 | — | — | CN | disclosed |
| CN-104066730-B | Heterocyclic compounds and their use as type III receptor tyrosine kinase modulators | 埃姆比特生物科学公司 | 2017-03-08 | — | — | CN | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| CN-1052009-C | Platinum complex and malignant tumor treating drug containing the same | SS PHARMACEUTICAL CO (JP) | 2000-05-03 | — | — | CN | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0686640-B1 | Platinum complex and malignant tumor treating drug containing the same | SS PHARMACEUTICAL CO (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5498780-A | Platinum complex and malignant tumor treating drug containing the same | SS PHARMACEUTICAL CO., LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| CN-1116206-A | Platinum complex and malignant tumor treating drug containing the same | SS PHARMACEUTICAL CO (JP) | 1996-02-07 | — | — | CN | disclosed |
| EP-0686640-A1 | Platinum complex and malignant tumor treating drug containing the same | SS PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0386940-A1 | 6-Beta-(alpha-etherified oxymino)-acyl amino penicillins | BEECHAM GROUP PLC (GB) | 1990-09-12 | — | — | EP | disclosed |
| EP-0126088-A1 | ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS | E.R. SQUIBB & SONS, INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-4463015-A | Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation | E. R. SQUIBB & SONS, INC. (US) | 1984-07-31 | — | — | US | disclosed |
| WO-1984000754-A1 | ARYL SUBSTITUTED 7-OXABICYCLOHEPTANE COMPOUNDS | SQUIBB & SONS INC (US) | 1984-03-01 | — | — | WO | disclosed |